Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Improving Understanding of Fexofenadine Pharmacokinetics to Assess Pgp Phenotypic Activity in Older Adult Patients Using Population Pharmacokinetic Modeling.

Clinical pharmacokinetics - 1 Feb 2025

Gaspar Frédéric, Jacost-Descombes Celestin, Gosselin Pauline, Reny Jean-Luc, Guidi Monia, Csajka Chantal, Samer Caroline, Daali Youssef, Terrier Jean

Abstract excerpt

BACKGROUND AND OBJECTIVE: Fexofenadine is commonly used as a probe substrate to assess P-glycoprotein (Pgp) activity. While its use in healthy volunteers is well documented, data in older adult and polymorbid patients are lacking. Age- and disease-related physiological changes are expected to affect the pharmacokinetics of fexofenadine. This study aims to investigate the pharmacokinetics of fexofenadine in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Aged

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Share to Models, Biological

Share to Phenotype

Share to Renal Insufficiency

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 39798016
DOI: 10.1007/s40262-024-01470-4
PMCID: PMC11782438

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 17 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improving Understanding of Fexofenadine Pharmacokinetics to Assess Pgp Phenotypic Activity in Older Adult Patients Using Population Pharmacokinetic Modeling.PMID 39798016Read ↗

Application of Physiologically Based Pharmacokinetic Modeling to Optimize Assessment of Age-Related Fluoxetine Accumulation in the Elderly.Semantic proximity Read ↗

Multi-factorial pharmacokinetic interactions: unraveling complexities in precision drug therapySemantic proximity Read ↗

Limitations of fexofenadine limited sampling strategy using plasma concentrations and partial area under the concentration-time curve to estimate transporter activity in healthy adults.Semantic proximity Read ↗

A Digital Twin of Glimepiride for Personalized and Stratified Diabetes TreatmentSemantic proximity Read ↗

PBPK modeling of the antidepressant doxepin incorporating CYP2D6 genotype for precision pharmacotherapy.Semantic proximity Read ↗

Understanding adefovir pharmacokinetics as a component of a transporter phenotyping cocktail.Semantic proximity Read ↗

Absorption, Distribution, Metabolism, and Excretion of Icenticaftor (QBW251) in Healthy Male Volunteers at Steady State and In Vitro Phenotyping of Major Metabolites.Semantic proximity Read ↗

Measuring pharmacogenetics in special groups: geriatrics.Semantic proximity Read ↗

Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions.Semantic proximity Read ↗

The role of the efflux transporter, P‐glycoprotein, at the blood–brain barrier in drug discoverySemantic proximity Read ↗

PharmGKB summary: Efavirenz pathway, pharmacokinetics.Semantic proximity Read ↗

Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.